Ask what remains unfinished behind a completed count
My contribution to a board
I would help a board examine the connection between what a production system counts and what its customers can actually use. My experience includes a layout that defeated a fold, a capital proposal aimed at the wrong process, delivery measures that concealed large late quantities and approvals that covered only part of a programme. These are different ways in which a local result can appear complete while the enterprise promise remains unfinished. I can contribute questions about the next use, the source of permission and the conditions of a proposed result. I would not bring authority to approve pharmaceutical language or clinical decisions. I have presented to our board but have never served as a statutory director. A useful first appointment would place my operating perspective alongside complementary financial, commercial and sector expertise, with a chair who expects me to learn the whole business and challenge my own assumptions.
Judgement in practice
01
Accepting the consequence of a locally efficient layout
My 2017 approval improved the apparent sheet yield but failed to account properly for the later fold. We held 1.2 million leaflets, remade 900,000 and released 300,000 after separate review. Rework cost ₹38 lakh and the replacement quantity was five working days late. In oversight, I would ask whether a proposed efficiency has been followed into the next operation and whether management's account includes the decision that created the problem. The hold was valuable, but it did not remove my responsibility or the commercial cost. I would keep technical acceptance with qualified colleagues and ask how their requirements inform the original choice, rather than reward a department for producing work another cannot use.
02
Distinguishing a capital rating from an operating result
The reviewed job mix needed eighteen million folded leaflets each month against sixteen million folding capability. The board chose a ₹3.8 crore folding programme instead of a ₹6.4 crore press proposal. The installed rating became twenty million, while the specified later month's completed output was 17.2 million. I would ask a board to keep the constraint, approved scope and observed result separate. A capital project can be installed without every operating assumption being demonstrated. The difference between the proposals is not automatically a like-for-like saving, and a rated capability is not a completed delivery count. My contribution would be to test whether the resource decision follows the actual production route and whether remaining performance questions are still visible after approval.
03
Making unequal late orders visible in the same cohort
Ninety-six of 120 orders were on time, producing an 80% order result. They contained fourteen million of thirty million leaflets, approximately 46.7% of the units; the twenty-four late orders contained sixteen million. I would help a board ask which distribution a performance measure obscures and whether the customer's original commitment has been preserved. The quantity view should supplement rather than automatically erase the order view, because small urgent jobs can matter too. Correcting the report did not complete the late work. The governance contribution is to improve the question management must answer without confusing more candid information with an achieved operating recovery or taking over the scheduling decisions that remain management's responsibility.
My first year on a board
I would begin with the receiving company's complete business model and the promises that connect its commercial and operating work. Through the chair's induction process, I would learn how management describes capacity, customer commitments and unresolved decisions, then follow a few important proposals from their source evidence into the board account. I would also study the financial, people and sector matters outside my familiar production environment. My questions should help the board assess the enterprise, not make managers prepare a second operating review for me or invite direct instructions to their teams. I would ask for feedback on the usefulness and proportion of my interventions. A successful first year would improve my collective judgement and broaden my understanding of the receiving business, while making my practical experience useful to colleagues with different expertise. I would expect to revise some assumptions rather than arrive with a factory method already chosen.
Conflicts and their management
Before receiving confidential board material, I would disclose my current executive role and relationships through Nevqumi's owners, investor, customers, suppliers and service providers. Although I hold no shares or statutory seat, those connections can still matter to the proposed appointment. I would obtain employer consent and ask the receiving company to arrange qualified review of independence, eligibility and applicable company-law or listing requirements, including relevant committee and directorship limits. A declared relationship is not automatically a manageable one. I would consider whether exclusions needed to address conflicts would leave enough scope for a useful contribution. Customer files, pricing, production methods and protected commercial information from my present work would not become examples for another board's confidential deliberations. The review would need to continue as relationships changed, with the option to decline or step back if the conditions no longer supported proper service.
My independence statement
I hold no statutory directorship, personal shares or employee-vehicle allocation. My executive role and relationships with Nevqumi's family owners, investor, customers and suppliers still require appointment-specific review; their absence from a share register would not establish independence.
Board and committee exposure
Presented to the Board or a committee
Nevqumi Printed Healthcare Components
Operating and capital proposals presented through the CEO
January 2022 onward
Explains production constraints, delivery measures and the costs of revised release or packing arrangements; no statutory appointment.